Connect with us

Markets

Ginkgo Bioworks (DNA) Partners with Merck to Revolutionize Biologic Manufacturing

Published

on

Ginkgo Bioworks (NYSE: DNA), a pioneering biotechnology company at the forefront of cell programming and biosecurity, has taken a significant stride towards advancing biologic manufacturing by announcing a groundbreaking collaboration with Merck (known as MSD outside of the United States and Canada). The partnership aims to revolutionize biologic drug production by leveraging Ginkgo’s cutting-edge platform and Merck’s expertise in pharmaceutical development.

The strategic alliance, officially unveiled today, represents a formidable force in the biotechnology industry, with both companies bringing their unique strengths to the table. Ginkgo Bioworks, renowned for its advanced cell programming technology, is dedicated to engineering organisms to produce valuable compounds, while Merck has established itself as a global pharmaceutical giant, known for its extensive experience in drug research, development, and manufacturing.

Want HOT Stock Alerts?

Text “STOCKS” to 855-261-8342

At the core of this collaboration lies the pursuit of improving biologic manufacturing processes. Biologics, which are therapeutic drugs derived from living organisms, have demonstrated tremendous potential in treating a wide range of diseases, including cancer, autoimmune disorders, and infectious diseases. However, their complex nature and sensitive production requirements often present challenges in large-scale manufacturing.

Ginkgo will leverage its proprietary cell programming platform, which enables precise engineering and control of microorganisms, to optimize the production of biologics. By harnessing the power of synthetic biology, the company aims to enhance the efficiency, scalability, and cost-effectiveness of biologic drug manufacturing processes.

As part of the partnership, Merck will contribute its vast experience in the pharmaceutical industry, providing invaluable insights into drug development and regulatory requirements. By combining their expertise, Ginkgo and Merck aim to accelerate the discovery and development of new biologic drugs and streamline their manufacturing to reach patients in need more efficiently.

Want HOT Stock Alerts?

Text “STOCKS” to 855-261-8342

Jason Kelly, CEO and Co-founder of Ginkgo Bioworks, expressed his enthusiasm about the collaboration, stating, “We are thrilled to join forces with Merck, a world leader in pharmaceuticals, to address the challenges in biologic drug manufacturing. By bringing together Ginkgo’s cutting-edge technology and Merck’s vast expertise, we can significantly advance the production of life-saving therapies and make them more accessible to patients worldwide.”

In addition to optimizing existing biologic manufacturing processes, the partnership will also focus on exploring new avenues for drug development and delivery. The synergistic collaboration between Ginkgo and Merck is expected to foster a more robust pipeline of biologics with diverse applications across various therapeutic areas.

Both companies share a strong commitment to biosecurity, ensuring that their technologies and manufacturing processes uphold the highest safety standards and mitigate any potential risks associated with biotechnology advancements.

The news of the collaboration has been met with enthusiasm and anticipation from investors and industry experts alike, with Ginkgo Bioworks’ stock (NYSE: DNA) experiencing a surge in value following the announcement.

The joint efforts of Ginkgo Bioworks and Merck hold the promise of propelling the biotechnology industry forward, bringing us closer to a future where groundbreaking biologic drugs are more efficiently developed, manufactured, and made available to patients globally.

Markets

Temasek to speculate as much as $198 million in Australian ETF supervisor Betashares

Published

on

© Reuters. FILE PHOTO: Temasek logo is seen in this illustration taken November 30, 2022. REUTERS/Dado Ruvic/Illustration/File Photo

(Reuters) – Singapore-based funding agency Temasek Holdings will make investments as much as A$300 million ($198.4 million) in Australian exchange-traded fund supervisor Betashares, the corporate stated on Monday.

The funding is anticipated to drive the growth of Betashares’ choices in Australia and abroad, it stated in a press release.

With the funding, Temasek will maintain an undisclosed minority stake in Betashares, becoming a member of its employees members and personal fairness agency TA Associates as shareholders, it added.

The Australian ETF trade’s market capitalisation reached A$177.5 billion in 2023, boosted by internet inflows of A$15 billion, in response to the most recent information compiled by Betashares.

Betashares, one of many nation’s greatest ETF corporations, manages over A$38 billion in belongings and serves over 1,000,000 traders in Australia, in response to its web site.

“The funding by Temasek will assist speed up the subsequent part of our journey, each organically in addition to by means of acquisitions and strategic investments,” Betashares Founder and CEO Alex Vynokur stated.

Temasek manages belongings value S$382 billion ($282.36 billion) as of March 31, 2023, and its portfolio consists of corporations like Alibaba (NYSE:), DBS Group (OTC:), and Tencent, amongst others, in response to Temasek’s web site.

($1 = 1.5124 Australian {dollars})

($1 = 1.3529 Singapore {dollars})

Continue Reading

Markets

5 Issues to Know in Crypto This Week: BTC-Spot ETFs Take pleasure in 4 Week Influx Streak

Published

on

Ripple Contributions Spotlight Significance of the US Presidential Election

On Wednesday (Might 29), Ripple CEO Brad Garlinghouse introduced a $25 million contribution to Fairshake. Fairshake helps candidates within the US dedicated to securing the US as the house to innovators constructing the subsequent era of the web.

Republican Get together front-runner Donald Trump planted crypto into the US Presidential Election Race, saying,

“In the event you like crypto in any kind…and it is available in many types…if you happen to’re in favor of crypto, you higher vote Trump.”

Earlier than the launch of US BTC-spot ETFs, 52 million Individuals owned crypto. The Trump plug might additionally affect the Biden administration to rethink its place on crypto and innovation.

On Thursday (Might 30), Donald Trump turned the primary former President to be discovered responsible on felony expenses. Regardless of the responsible verdicts, Trump stays the Republican Get together front-runner, carrying the hopes of the crypto market.

There have been additionally SEC vs. Ripple case-related updates for buyers to contemplate. On Wednesday (Might 29), Ripple filed its reply letter, supporting the Movement to Seal. Ripple strengthened its argument to seal private inflation, together with its monetary statements.

After a court docket ruling on the Movement to Seal, the US courts will determine the penalty Ripple should pay for breaching US securities legal guidelines.

Furthermore, buyers anticipate the SEC to enchantment in opposition to the Programmatic Gross sales of XRP ruling after the case. The SEC plan stays an XRP headwind. Nevertheless, shifting sentiment towards crypto on Capitol Hill might finish SEC plans for an enchantment and gas hypothesis about an XRP-spot ETF market.

From Monday (Might 27) to Saturday (June 1), XRP was down 1.86% to $0.5184. Regardless of the weekly loss, XRP noticed beneficial properties of three.30% in Might.

Continue Reading

Markets

Fisher Sells Stake of As much as $3 Billion to Introduction, Abu Dhabi Fund

Published

on

(Lusso’s Information) — Personal fairness agency Introduction Worldwide and a unit of the Abu Dhabi Funding Authority are shopping for a minority stake in billionaire Ken Fisher’s Fisher Investments value as a lot as $3 billion.

Most Learn from Lusso’s Information

The transaction, wherein the acquirers will make investments at the very least $2.5 billion, values intently held Fisher at $12.75 billion, the money-management agency stated Sunday in a press release. The deal is a part of Ken Fisher’s property planning, in response to the corporate, and can let Fisher Investments proceed to function independently.

“Whereas my well being is great, this transaction with an atypically lengthy holding interval for a personal fairness transaction will guarantee FI’s long-term non-public independence and tradition ought to something untoward occur to me,” Fisher, 73, stated within the assertion.

Lusso’s Information Information and the Journal reported in January that Introduction had held talks to amass Fisher, each citing individuals with data of the matter. At the moment, Fisher issued a press release saying, “Fisher Investments just isn’t being purchased by Introduction Worldwide, or anybody else — plain and easy.” Introduction issued the same denial of the January stories.

Fisher Investments oversees $275 billion for greater than 150,000 purchasers together with people and establishments, the agency stated in its assertion Sunday.

Ken Fisher based the intently held agency in 1979, and final yr moved its headquarters to the Dallas suburb of Plano, Texas, after the best court docket in Washington state stated a capital positive factors tax on rich residents was constitutional.

The San Francisco native has an estimated internet value of $5.2 billion, in response to the Lusso’s Information Billionaires Index.

Introduction, which has made non-public fairness bets since 1989, counts monetary companies amongst its areas of focus and has backed corporations together with Worldpay and Vantiv, its web site exhibits. The Abu Dhabi Funding Authority, a sovereign wealth fund, was established in 1976 and employs an funding technique targeted on long-term worth, in response to the Sunday assertion.

The Wall Avenue Journal reported earlier Sunday that Introduction was nearing a deal to purchase a minority stake in Fisher.

–With help from Lin Cheng and Michelle F. Davis.

Most Learn from Lusso’s Information Businessweek

©2024 Lusso’s Information L.P.

Continue Reading

Trending